Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doxorubicin-Transdrug in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.

Trial Profile

Doxorubicin-Transdrug in Advanced HepatoCellular Carcinoma A Randomized, Multicenter Phase 2-3 Study.

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 11 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin (Primary) ; Antineoplastics
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms DOTAHCC1
  • Sponsors BioAlliance Pharma
  • Most Recent Events

    • 11 Aug 2017 This trial has been Discontinued in Belgium, according to European Clinical Trials Database.
    • 11 Aug 2014 Status changed from suspended to completed as reported by European Clinical Trials Database record.
    • 06 Sep 2011 Preliminary results of 28 evaluable patients (of a planned 50) were presented at the annual congress of the International Liver Cancer Association, as reported in a BioAlliance Pharma media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top